1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Graphite Bio, Inc.
  6. Summary
    GRPH   US38870X1046

GRAPHITE BIO, INC.

(GRPH)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
2.360 USD   -9.92%
05/16Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
BU
05/16Graphite Bio, Inc. Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25 Annual Meeting
CI
05/13SVB Securities Adjusts Graphite Bio's Price Target to $16 from $18, Keeps Outperform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
2.28(c) 2.6(c) 2.48(c) 2.62(c) 2.36(c) Last
3 066 409 1 220 049 960 090 467 750 394 280 Volume
-0.87% +14.04% -4.62% +5.65% -9.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -105 M - -
Net cash position 2022 286 M - -
P/E ratio 2022 -1,26x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -145 M - -
Net cash position 2023 345 M - -
P/E ratio 2023 -0,96x
Yield 2023 -
Capitalization 137 M 137 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 91
Free-Float 90,4%
More Financials
Company
Graphite Bio, Inc. is a clinical-stage, gene editing company. The Company is developing a new class of therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The Company's lead product candidate, GPH101, is a differentiated approach with... 
Sector
Biotechnology & Medical Research
Calendar
05/18 | 11:30amPresentation
More about the company
Ratings of Graphite Bio, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about GRAPHITE BIO, INC.
05/16Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia..
BU
05/16Graphite Bio, Inc. Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thala..
CI
05/13SVB Securities Adjusts Graphite Bio's Price Target to $16 from $18, Keeps Outperform Ra..
MT
05/12GRAPHITE BIO, INC. Management's Discussion and Analysis of Financial Condition and Res..
AQ
05/12Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
BU
05/12Graphite Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11TRANSCRIPT : Graphite Bio, Inc. Presents at Bank of America 2022 Healthcare Conference, Ma..
CI
05/04Graphite Bio Announces Participation in Upcoming Investor Conferences
BU
05/03Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatm..
BU
05/03Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatm..
CI
05/03Graphite Bio Gets Fast Track Designation for GPH101 Sickle Cell Treatment
DJ
05/02Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Pr..
BU
04/14BTIG Starts Graphite Bio at Buy With $18 Price Target
MT
04/05GRAPHITE BIO : Initial Statement of Beneficial Ownership (Form 3)
PU
04/03SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Graph..
PR
More news
News in other languages on GRAPHITE BIO, INC.
05/16Graphite Bio, Inc. présente des données précliniques sur le remplacement du gène GPH102..
05/12Graphite Bio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/03Graphite Bio annonce que la FDA américaine a accordé la désignation Fast Track au GPH10..
03/23Graphite Bio Inc. annonce la formation d'un conseil consultatif scientifique
03/22Les actions de Graphite Bio chutent mardi après-midi après la dégradation de Morgan Sta..
More news
Analyst Recommendations on GRAPHITE BIO, INC.
More recommendations
Chart GRAPHITE BIO, INC.
Duration : Period :
Graphite Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRAPHITE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 2,36 $
Average target price 13,00 $
Spread / Average Target 451%
EPS Revisions
Managers and Directors
Joshua Lehrer-Graiwer President, Chief Executive Officer & Director
Alethia Young Chief Financial & Accounting Officer
Perry A. Karsen Chairman
Jerry Cacia Chief Technical Officer
Jane Grogan Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GRAPHITE BIO, INC.-81.01%137
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169